Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Catalent

Medical equipment maker Danaher Corp has expressed interest in taking over contract drugmaker Catalent Inc , Bloomberg News reported on Saturday, citing people familiar with the matter.

Danaher interested in buying life sciences firm Catalent- Bloomberg News

In September 2022, Danaher Corp. ( DHR , Financial) announced its intention to spin off its environmental and applied solutions segment into a separate publicly traded business in the fourth quarter of 2023. Called “EAS” for now until it gets an official name, the new company will include the water quality and product identification businesses.

Danaher: A Future-Focused Spinoff Value Play

Danaher's (DHR) Q4 results benefit from strong segmental performances and organic sales growth.

Danaher (DHR) Q4 Earnings & Revenues Beat, Increase Y/Y

Danaher Corporation (NYSE:DHR ) Q4 2022 Results Conference Call January 24, 2023 8:00 AM ET Company Participants John Bedford - Vice President-Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Rachel Vatnsdal - JPMorgan Vijay Kumar - Evercore ISI Scott Davis - Melius Research Dan Brennan - Cowen and Company Patrick Donnelly - Citi Operator Good day, everyone. My name is Todd, and I will be your conference facilitator this morning.

Danaher Corporation (DHR) Q4 2022 Earnings Call Transcript

The medical company's fourth-quarter earnings beat expectations, but analysts say investors are paying attention to other elements of the report.

Danaher Hit After Cutting Covid-Related Revenue From Growth Reports

Danaher (DHR) delivered earnings and revenue surprises of 16.67% and 9.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Tops Q4 Earnings and Revenue Estimates

WASHINGTON , Jan. 24, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2022.  All results in this release reflect only continuing operations unless otherwise noted.

Danaher Reports Fourth Quarter and Full Year 2022 Results

Hitachi Ltd

HTHIY vs. DHR: Which Stock Is the Better Value Option?

AbbVie

Abbott Labs

Becton, Dickinson and Co.

Bruker

DexCom

Edwards Lifesciences

Medtronic

Merck KGaA

Thermo Fisher Scientific

The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles.

Ranking The Diversified Healthcare Giants

Chevron

Johnson & Johnson

Mastercard

Microsoft

NextEra Energy

Tesla

Visa

Verizon

The fourth quarter earnings season is always the most important because it reveals the full year performance of the companies as well.

10 Biggest Companies Reporting Earnings in the 4th Week of Jan 2023

High raw material costs and supply-chain disruptions are likely to have hurt Danaher's (DHR) Q4 earnings. However, the top line is likely to have benefited from an expected increase in revenues at the Environmental & Applied Solutions segment.

Will Cost Headwinds Dampen Danaher's (DHR) Q4 Earnings?

Take-Two Interactive Software

UnitedHealth Group

Ron Baron (Trades, Portfolio) and Daniel Loeb (Trades, Portfolio) are two gurus that follow very different investing styles. While both focus on the long term, Baron's Baron Funds aims to invest in value opportunities led by quality management teams, while Loeb's Third Point LLC is focused on activist and special situations investing.

3 Stocks Ron Baron and Daniel Loeb Agree On

Caterpillar

CME Group

Canadian Pacific Kansas City Limited

Deere & Company

Duke Energy

Extra Space Storage

Huntington Bancshares

Home Depot

Huntington Ingalls Industries

L3Harris

Lockheed Martin

Nasdaq

Northrop Grumman

Norfolk Southern

PepsiCo

Public Storage

Raytheon Technologies

Schwab US Dividend Equity ETF

Union Pacific

Vanguard Dividend Appreciation ETF

Valero Energy

Vanguard High Dividend Yield ETF

As requested by many, I decided to dedicate an article to my personal dividend growth portfolio, consisting of more than 90% of my net worth. I start by explaining my strategy and approach, followed by a discussion of the benefits that come with dividend (growth) investment strategies.

My 6-Figure Market-Beating Dividend Growth Portfolio

In this article, I revisit the life sciences "picks and shovels" market leaders Danaher Corporation and Thermo Fisher Scientific Inc. I will review changes since the initial comparative piece two quarters ago.

We Have A Winner! Revisiting Danaher And Thermo Fisher

Strength across the Life Sciences segment, inorganic activities and DBS initiatives bode well for Danaher's (DHR) growth. Shareholder-friendly policies add to the stock's appeal.

Here's Why Hold Strategy is Apt for Danaher (DHR) Stock Now

Danaher Corporation (NYSE:DHR ) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 4:30 PM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Perfect.

Danaher Corporation (DHR) 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Benefiting from strong growth in Cepheid's molecular diagnostics among other factors, Danaher (DHR) improves its adjusted core revenue growth guidance for the fourth quarter of 2022.

Danaher (DHR) Provides Improved Q4 Core Revenue Growth Guidance

Danaher Corp. DHR, +1.01% on Monday said it expected fourth-quarter sales to rise in the “low-single-digit percent range,” despite what executives said was a “challenging environment” for the maker of diagnostic and life-sciences equipment. That forecast was more upbeat than FactSet's expectations for a 5% fourth-quarter sales decline to $7.71 billion.

Danaher sees Q4 sales increasing in ‘low-single-digit percent range'

OTTAWA, Canada--( BUSINESS WIRE )--Virica Biotech Inc. (“Virica”), a leading supplier and developer of viral enhancers for scaling of viral medicines, announced today that Beth Thompson-Webb will be joining the company as Chief Commercial Officer (CCO), effective January 9, 2023. Based out of Boston, MA, Ms. Thompson-Webb will be leading Virica's commercial efforts to drive global sales and new business growth.

Virica Biotech Announces Industry Veteran, Beth Thompson-Webb, as Chief Commercial Officer

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Danaher (DHR) Could Beat Earnings Estimates Again

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

How to Find Strong Multi-Sector Conglomerates Stocks Slated for Positive Earnings Surprises

WASHINGTON , Dec. 27, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2022 on Tuesday, January 24, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Danaher Schedules Fourth Quarter 2022 Earnings Conference Call

Apple

Activision Blizzard

Hershey

Kraft Heinz

Occidental Petroleum

Progressive

The outlook for stocks in 2023 is very uncertain, with the risk of a recession. The Federal Reserve is very likely to increase interest rates throughout 2023.

10 Stocks For 2023

Humana

Pfizer

Cramer said that healthcare stocks have stayed relatively steady this year because they tend to be recession-resistant stocks.

Jim Cramer recommends these 5 healthcare stocks in 2023

Danaher (DHR) gains from strength across its core Life Sciences segment, benefits from the DBS initiatives and acquired assets. The company's efforts to add shareholder value hold promise.

Danaher (DHR) Up 14% in 6 Months: What's Driving the Stock?

News for Danaher Stock (DHR)